<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751491</url>
  </required_header>
  <id_info>
    <org_study_id>SARD55</org_study_id>
    <nct_id>NCT00751491</nct_id>
  </id_info>
  <brief_title>Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)</brief_title>
  <acronym>RACE</acronym>
  <official_title>Randomized Comparison of Adenosin Intracoronary Infusion and Clopidogrel Pretreatment on Myonecrosis Occurence in Elective PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous coronary intervention (PCI) is associated with up to 30% incidence of
      myonecrosis, as reflected by elevation of cardiac enzymes in a successful procedure. Apart
      from side-branch occlusion, intimal dissection and coronary spasm, a possible aetiology of
      myonecrosis after PCI might be distal embolization of atherogenic materials from plaque
      disruption causing obstruction of blood ﬂow at capillary level resulting in micro-infarction.
      Recent studies have suggested that pretreatment with adenosine in the cath lab and
      Clopidogrel and statins greater than 6 hours before may be associated with a reduction in
      infarct size after reperfusion therapy for acute myocardial infarction. Whether pretreatment
      with adenosine decreases the incidence of myonecrosis in patients undergoing non-urgent PCI
      is not fully known. The investigators propose that adenosine-induced hyperaemia can
      potentially ameliorate the deleterious effects of distal embolization associated with
      non-urgent PCI through dilatation of the microvasculature. Mechanistically, this may reduce
      capillary obstruction by facilitating the throughput passage of embolized platelet thrombi
      out to the venous end of the coronary circulation, thereby reducing the incidence of post-PCI
      myonecrosis. In this prospective, randomized, open-label study, the investigators evaluated
      the incidence of myonecrosis after non-urgent PCI with a treatment with intracoronary
      adenosine compared with pretreatment of loading dose of Clopidogrel 300/600 mg &gt;/&lt; 6 hours.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20%</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>0%</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stable Angina</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosin</intervention_name>
    <description>Intracoronary Adenosin 50 microg;</description>
    <arm_group_label>A</arm_group_label>
    <other_name>PERCUTANEOUS CORONARY ANGIOGRAPHY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>no intervention</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 300/600 mg</description>
    <arm_group_label>III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline creatine-kinase (CK) and creatine-kinase-myocardial band (CK-MB) had to be
             within normal limits (a normal CK and CK-MB and elevated troponin allowed inclusion)

        Exclusion Criteria:

          -  Occlusion resulting in Thrombolysis In Myocardial Infarction (TIMI) grade 0 antegrade
             ﬂow

          -  Thrombus-laden lesions

          -  Significant left main coronary stenosis

          -  Left ventricular ejection fraction 30%

          -  Inability to give informed consent

          -  Bradycardia with heart rate below 50 b.p.m.

          -  Allergy to adenosine

          -  The occurrence of myo-cardial infarction within one week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GENNARO SARDELLA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DEPT.CARDIOLOGY-POLICLINICO UMBERTO I-SAPIENZA UNIVERSITY OF ROME</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MASSIMO MANCONE, MD</last_name>
    <role>Study Director</role>
    <affiliation>DEPT.CARDIOLOGY-POLICLINICO UMBERTO I-SAPIENZA UNIVERSITY OF ROME</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GENNARO SARDELLA, MD</last_name>
      <phone>+390649979035</phone>
      <email>rino.sardella@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>GENNARO SARDELLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2008</study_first_submitted>
  <study_first_submitted_qc>September 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <last_update_submitted>May 5, 2009</last_update_submitted>
  <last_update_submitted_qc>May 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>GENNARO SARDELLA</name_title>
    <organization>POLICLINICO UMBERTO I-SAPIENZA UNIVERSITY OF ROME</organization>
  </responsible_party>
  <keyword>Stable angina</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Myonecrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 3, 2009</submitted>
    <returned>December 4, 2009</returned>
    <submitted>December 9, 2009</submitted>
    <returned>January 12, 2010</returned>
    <submitted>January 13, 2010</submitted>
    <returned>February 4, 2010</returned>
    <submitted>October 25, 2010</submitted>
    <returned>November 24, 2010</returned>
    <submitted>January 3, 2013</submitted>
    <returned>February 5, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

